Key result
Between 2010 and 2022, ATG use for GVHD prophylaxis increased in HLA-matched PBSCT and unrelated HLA 1-locus mismatched BMT/PBSCT, but decreased in related HLA haplo-PBSCT from 67.7% to 11.2%.
Why the study?
Trends in GVHD prophylaxis using ATG in allogeneic hematopoietic stem cell transplantation across different donor types and stem cell sources were not well characterized over time.
Observational (n=27,091)
Yes
The use of ATG for GVHD prophylaxis in Japan has increased across most transplantation types from 2010 to 2022, except in related-HLA haplo-PBSCT where it decreased due to the rise of posttransplant cyclophosphamide.
Answers are grounded in this paper and cite their sources.
Trends in ATG-based GVHD prophylaxis vary by donor and source; leaves open optimal regimen standardization.
Graft-versus-host disease (GVHD) prophylaxis using antithymocyte globulin (ATG) has been well-established in allogeneic hematopoietic stem cell transplantation. We collected data on GVHD prophylaxis from 27,091 cases of hematological malignancies undergoing bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) from 2010 to 2022. Annual trends in GVHD prophylaxis were analyzed based on donor type, stem cell source or HLA compatibility. The number of GVHD prophylaxis using ATG was increased in related-HLA matched-PBSCT [2010: n＝6 (1.6%), 2022: n＝42 (14.1%)], unrelated-HLA matched-PBSCT [2010: n＝0 (0.0%), 2022: n＝80 (43.0%)], unrelated-HLA 1-locus mismatched-BMT [2010: n＝36 (9.6%), 2022: n＝97 (40.4%)], and unrelated-HLA 1-locus mismatched-PBSCT [2010: n＝0 (0.0%), 2022: n＝64 (59.3%)]. Conversely, ATG use decreased in related-HLA haplo-PBSCT [2010: n＝111 (67.7%), 2022: n＝63 (11.2%)] due to the increasing use of posttransplant cyclophosphamide (PTCy). This study highlights the variation in GVHD prophylaxis trends using ATG across transplantation types.
No takes yet. Share an insight, caveat, or question.
Shiratori et al. (2025) conducted an observational in Hematological malignancies undergoing BMT and PBSCT (n=27,091). Antithymocyte globulin (ATG) for GVHD prophylaxis vs. Non-ATG or posttransplant cyclophosphamide (PTCy) was evaluated on Annual trends in GVHD prophylaxis using ATG based on donor type, stem cell source, or HLA compatibility. Between 2010 and 2022, ATG use for GVHD prophylaxis increased in HLA-matched PBSCT and unrelated HLA 1-locus mismatched BMT/PBSCT, but decreased in related HLA haplo-PBSCT from 67.7% to 11.2%.
Synapse has enriched 10 related papers. Consider them for comparative context: